vs
Side-by-side financial comparison of bioAffinity Technologies, Inc. (BIAF) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $1.6M, roughly 444.8× bioAffinity Technologies, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs -197.0%, a 216.1% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -27.8%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $-2.6M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs -18.6%).
bioAffinity Technologies, Inc. is a clinical-stage biotechnology firm focused on developing non-invasive in vitro diagnostic tests for early detection of cancer and respiratory diseases. It serves global healthcare markets, with a core mission to deliver accessible, high-accuracy diagnostic solutions that improve patient outcomes and reduce overall healthcare system costs.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
BIAF vs MEDP — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $708.5M |
| Net Profit | $-3.1M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | -196.9% | 21.6% |
| Net Margin | -197.0% | 19.1% |
| Revenue YoY | -27.8% | 32.0% |
| Net Profit YoY | -5.7% | 15.5% |
| EPS (diluted) | $-3.59 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $708.5M | ||
| Q3 25 | $1.4M | $659.9M | ||
| Q2 25 | $1.3M | $603.3M | ||
| Q1 25 | $1.9M | $558.6M | ||
| Q4 24 | $2.2M | $536.6M | ||
| Q3 24 | $2.4M | $533.3M | ||
| Q2 24 | $2.4M | $528.1M | ||
| Q1 24 | $2.4M | $511.0M |
| Q4 25 | $-3.1M | $135.1M | ||
| Q3 25 | $-5.1M | $111.1M | ||
| Q2 25 | $-4.1M | $90.3M | ||
| Q1 25 | $-2.7M | $114.6M | ||
| Q4 24 | $-3.0M | $117.0M | ||
| Q3 24 | $-2.0M | $96.4M | ||
| Q2 24 | $-2.1M | $88.4M | ||
| Q1 24 | $-2.0M | $102.6M |
| Q4 25 | -196.9% | 21.6% | ||
| Q3 25 | -158.6% | 21.5% | ||
| Q2 25 | -198.2% | 20.9% | ||
| Q1 25 | -141.7% | 20.3% | ||
| Q4 24 | -133.5% | 23.4% | ||
| Q3 24 | -84.0% | 21.1% | ||
| Q2 24 | -87.1% | 19.9% | ||
| Q1 24 | -80.8% | 20.4% |
| Q4 25 | -197.0% | 19.1% | ||
| Q3 25 | -349.3% | 16.8% | ||
| Q2 25 | -319.9% | 15.0% | ||
| Q1 25 | -143.5% | 20.5% | ||
| Q4 24 | -134.4% | 21.8% | ||
| Q3 24 | -85.1% | 18.1% | ||
| Q2 24 | -88.0% | 16.7% | ||
| Q1 24 | -81.5% | 20.1% |
| Q4 25 | $-3.59 | $4.65 | ||
| Q3 25 | $-4.74 | $3.86 | ||
| Q2 25 | $-0.17 | $3.10 | ||
| Q1 25 | $-0.16 | $3.67 | ||
| Q4 24 | $-17.27 | $3.67 | ||
| Q3 24 | $-4.84 | $3.01 | ||
| Q2 24 | $-0.19 | $2.75 | ||
| Q1 24 | $-0.20 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.4M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.3M | $459.1M |
| Total Assets | $11.0M | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.4M | $497.0M | ||
| Q3 25 | $7.7M | $285.4M | ||
| Q2 25 | $802.8K | $46.3M | ||
| Q1 25 | $444.7K | $441.4M | ||
| Q4 24 | $1.1M | $669.4M | ||
| Q3 24 | $756.6K | $656.9M | ||
| Q2 24 | $801.3K | $510.9M | ||
| Q1 24 | $2.5M | $407.0M |
| Q4 25 | $7.3M | $459.1M | ||
| Q3 25 | $8.9M | $293.6M | ||
| Q2 25 | $-2.1M | $172.4M | ||
| Q1 25 | $1.4M | $593.6M | ||
| Q4 24 | $2.6M | $825.5M | ||
| Q3 24 | $3.1M | $881.4M | ||
| Q2 24 | $3.4M | $763.6M | ||
| Q1 24 | $5.3M | $671.5M |
| Q4 25 | $11.0M | $2.0B | ||
| Q3 25 | $11.5M | $1.8B | ||
| Q2 25 | $4.8M | $1.6B | ||
| Q1 25 | $5.5M | $1.9B | ||
| Q4 24 | $6.5M | $2.1B | ||
| Q3 24 | $6.6M | $2.1B | ||
| Q2 24 | $6.7M | $1.9B | ||
| Q1 24 | $8.0M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.6M | $192.7M |
| Free Cash FlowOCF − Capex | $-2.6M | $188.1M |
| FCF MarginFCF / Revenue | -160.7% | 26.6% |
| Capex IntensityCapex / Revenue | 0.0% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $-9.4M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.6M | $192.7M | ||
| Q3 25 | $-2.5M | $246.2M | ||
| Q2 25 | $-2.6M | $148.5M | ||
| Q1 25 | $-1.6M | $125.8M | ||
| Q4 24 | $-1.7M | $190.7M | ||
| Q3 24 | $-1.7M | $149.1M | ||
| Q2 24 | $-1.5M | $116.4M | ||
| Q1 24 | $-2.3M | $152.7M |
| Q4 25 | $-2.6M | $188.1M | ||
| Q3 25 | $-2.5M | $235.5M | ||
| Q2 25 | $-2.7M | $142.4M | ||
| Q1 25 | $-1.7M | $115.8M | ||
| Q4 24 | $-1.7M | $183.0M | ||
| Q3 24 | $-1.7M | $138.5M | ||
| Q2 24 | $-1.6M | $103.5M | ||
| Q1 24 | $-2.4M | $147.2M |
| Q4 25 | -160.7% | 26.6% | ||
| Q3 25 | -171.8% | 35.7% | ||
| Q2 25 | -209.6% | 23.6% | ||
| Q1 25 | -91.3% | 20.7% | ||
| Q4 24 | -76.0% | 34.1% | ||
| Q3 24 | -73.1% | 26.0% | ||
| Q2 24 | -65.1% | 19.6% | ||
| Q1 24 | -99.2% | 28.8% |
| Q4 25 | 0.0% | 0.6% | ||
| Q3 25 | 0.3% | 1.6% | ||
| Q2 25 | 1.1% | 1.0% | ||
| Q1 25 | 2.7% | 1.8% | ||
| Q4 24 | 0.0% | 1.4% | ||
| Q3 24 | 0.4% | 2.0% | ||
| Q2 24 | 1.2% | 2.4% | ||
| Q1 24 | 1.7% | 1.1% |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIAF
Segment breakdown not available.
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
